Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

In a remarkable display of market confidence, Verona Pharma (NASDAQ:VRNA)'s stock has surged to an all-time high, reaching a ...

The Czech prime minister said Tuesday his country no longer needed to import Russian oil, following the completion of an expansion of the Transalpine Pipeline (TAL) from Italy. The contract to expand ...

The bullish stance is based on the potential of Verona Pharma's Ohtuvayre™, which is expected to address a substantial total addressable market (TAM) of approximately 8.6 million symptomatic patients ...

A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods gained and the significance of the new drugs and biologics that these ...

The company’s flagship product, Ohtuvayre, has a unique mechanism that combines bronchodilation and anti-inflammation for COPD treatment, potentially addressing unmet medical needs in a market ...

Looking beyond the current success of Ohtuvayre's launch, Truist Securities is also anticipating updates throughout 2025 regarding Verona Pharma's pipeline. These updates are expected to include ...

Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's ...